ORPHA:685010
Mesothelioma of the tunica vaginalis
Also known as: Malignant mesothelioma of the tunica vaginalis
Publications
306
67th percentile
Trials
0
Interventional, condition-specific
Researchers
1,068
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0975890
- UMLS:C3494988
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
306 matched papers (104 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 468 for broader category mesothelioma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
306
306 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
306 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
104 in the last 10 years · medium confidence · 67th percentile (publications denominator)
Phrase hits: 306 · MeSH hits: 0
Who's working on it?
1,068
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Vimercati L5 papers · 2025
COR Puglia, Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy.
Papers in Europe PMC - 02Cavone D4 papers · 2025
COR Puglia, Section of Occupational Medicine "B. Ramazzini", Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy.
Papers in Europe PMC - 03Consonni D4 papers · 2025
Occupational Health Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy dario.consonni@unimi.it.
Papers in Europe PMC - 04Mensi C4 papers · 2025
Occupational Health Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 05Caputi A3 papers · 2024
Interdisciplinary Department of Medicine (DIM), Unit of Occupational Medicine, Section Occupational Medicine. "B. Ramazzini", University Aldo Moro of Bari Medical School, 11 G. Cesare Square, 70124, Bari, Italy.
Papers in Europe PMC - 06De Maria L3 papers · 2024
Interdisciplinary Department of Medicine (DIM), Unit of Occupational Medicine, Section Occupational Medicine. "B. Ramazzini", University Aldo Moro of Bari Medical School, 11 G. Cesare Square, 70124, Bari, Italy.
Papers in Europe PMC - 07Ferri GM3 papers · 2024
Interdisciplinary Department of Medicine (DIM), Unit of Occupational Medicine, Section Occupational Medicine. "B. Ramazzini", University Aldo Moro of Bari Medical School, 11 G. Cesare Square, 70124, Bari, Italy.
Papers in Europe PMC - 08Golka K3 papers · 2022
Leibniz-Institut für Arbeitsforschung an der TU Dortmund (IfADo), Ardeystr. 67, 44139, Dortmund, Deutschland. golka@ifado.de.
Papers in Europe PMC - 09Gupta R3 papers · 2011Papers in Europe PMC
- 10Kajo K3 papers · 2016Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 468 trials are registered for mesothelioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
468 interventional trials matched mesothelioma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: mesothelioma
468
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04996017·RECRUITING·Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Conditions: Mesotheliomas Pleural·Matched via name phrase
- NCT06037941·RECRUITING·Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Conditions: Malignant Pleural Mesothelioma·Matched via name phrase
- NCT05568680·RECRUITING·SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Conditions: Ovarian Cancer · Cholangiocarcinoma Recurrent · Mesothelioma, Malignant·Matched via name phrase
- NCT07330271·RECRUITING·PTC-Guided Therapy for Peritoneal Mesothelioma
Conditions: Peritoneal Mesothelioma·Matched via name phrase
- NCT04104776·RECRUITING·A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Conditions: Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell · Mesothelioma, Malignant·Matched via name phrase
- NCT05107674·RECRUITING·A Study of NX-1607 in Adults With Advanced Malignancies
Conditions: Ovarian Cancer, Epithelial · Gastric Cancer · GastroEsophageal Junction (GEJ) Cancer · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT04024917·RECRUITING·Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
Conditions: Peritoneal Carcinomatosis · Pseudomyxoma Peritonei · Mesothelioma Peritoneum·Matched via name phrase
- NCT06535607·RECRUITING·Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Conditions: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) · Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)·Matched via name phrase
- NCT06726564·RECRUITING·A Study of MT027 in Patients with Pleural Malignant Tumors
Conditions: Advanced Malignant Solid Tumor · Malignant Pleural Effusion · Pleura Carcinoma · Pleural Mesothelioma·Matched via name phrase
- NCT07277413·RECRUITING·A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Conditions: NSCLC Adenocarcinoma · Gastroesophageal Cancer (GC) · Gastric Adenocarcinoma · Adenocarcinoma of Esophagus·Matched via name phrase
- NCT06452160·RECRUITING·A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Conditions: Mesothelioma · Epithelioid Hemangioendothelioma(EHE) · Solid Tumor·Matched via name phrase
- NCT06057935·RECRUITING·A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Conditions: Malignant Peritoneal Mesothelioma · Peritoneal Mesothelioma · Mesothelioma · Mesothelioma, Malignant·Matched via name phrase
- NCT06652529·NOT YET RECRUITING·Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
Conditions: Solid Tumors (Phase 1) · Mesothelioma · Colorectal Carcinoma · Ovarian Cancer·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT03683680·RECRUITING·Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Conditions: Mesothelioma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mesothelioma of the tunica vaginalis" OR "Mesothelioma of tunica vaginalis" OR "Malignant mesothelioma of the tunica vaginalis" OR "Malignant mesothelioma of tunica vaginalis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mesothelioma of the tunica vaginalis" OR "Mesothelioma of tunica vaginalis" OR "Malignant mesothelioma of the tunica vaginalis" OR "Malignant mesothelioma of tunica vaginalis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"mesothelioma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (306) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-27T20:28:36.357Z
